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ABSTRACT: We reported the case of a patient in whom severe, and ultimately
fatal, pulmonary hypertension developed 1.5 yrs after transjugular intrahepatic porto-
systemic shunt (TIPS).  
Pulmonary artery pressures were not affected by 100% oxygen, prostacyclin or
nifedipine. Postmortem examinations showed pulmonary and vascular abnormali-
ties typical of pulmonary hypertension. 
Pulmonary artery pressures should be measured in each patient with otherwise
not readily explained dyspnoea following transjugular intrahepatic portosystemic
shunt.
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Transjugular intrahepatic portosystemic shunt (TIPS)
has recently been introduced as treatment for conse-
quences of portal hypertension, such as variceal haemorr-
hage and refractory ascites [1, 2].  Several complications
in placement of TIPS have been reported, including stent
dislodgement, haemobilia, liver capsule rupture, intra-
abdominal bleeding, encephalopathy, haemolysis, chole-
stasis, renal failure and sepsis [1–3].  We describe a patient
who developed pulmonary hypertension 1.5 yrs after
TIPS insertion.
Case report
A 45 year old man with alcoholic liver cirrhosis was
admitted to hospital due to bleeding from large gastric
varices. After initial control of the bleeding with endo-
scopic sclerotherapy, a TIPS was inserted.  After a year
without medical problems, the patient was readmitted due
to bleeding originating from a gastric varix.  Recatheteri-
zation with phlebography revealed subtotal stent steno-
sis and a large coronary vein feeding gastric varices. A
second stent was inserted inside the old one and emboliza-
tion of the coronary vein was performed.
Six months later, the patient presented with exertional
dyspnoea and syncope. His medication consisted of spiro-
nolactone, furosemide, lactulose and ranitidine. At phy-
sical examination, arterial and central venous pressures
were normal. Heart rate was 84 beats·min-1. No jaun-
dice, ascites, oedema, cyanosis or finger-clubbing was
found. Normal heart sounds and a short ejection mur-
mur at the left sternal border were noted. The lungs were
normal on examination.  The liver was felt 5 cm below
the right costal margin. 
Laboratory investigation showed mild iron deficiency
anaemia (haemoglobin 5.2 mmol·L-1).  Arterial blood gas
analysis was normal. Ventilatory function was normal:
total lung capacity (TLC) 7.89 L, and forced expiratory
volume in one second (FEV1) 3.67 L (95% predicted).
Transfer factor of the lungs for carbon monoxide was nor-
mal. Doppler ultrasound examination suggested normal
TIPS function. In contrast to the chest radiographic exami-
nation obtained before the first TIPS, the heart was
increased in size and lung vessels were prominent. The
lung parenchyma showed no abnormalities.  Cardiac ultra-
sound showed dilation of right atrium and right ventri-
cle, with insufficiency of the tricuspid valve.  The function
and dimensions of the left ventricle were considered nor-
mal. Pulmonary ventilation and perfusion scans were nor-
mal. Continuous registration of oxygen saturation during
the night revealed no periods of hypoxaemia. 
The patient was treated with blood transfusion and the
furosemide dosage was increased to 80 mg·day-1, with
good clinical response.
For further haemodynamic analysis, a Swan-Ganz ther-
modilution catheter and a radial artery line were inserted.
Baseline measurements were obtained whilst the patient
was breathing room air.  Several interventions were stud-
ied: 100% oxygen, infusion of prostacyclin at doses of
4 and 8 ng·kg-1·min and of nifedipine at 0.1, 0.15 and
0.2 mg·min-1 (table 1).  Measurements were obtained after
30 min stabilization. In between these interventions,
baseline conditions were reassumed for 30 min. These
measurements showed fixed pulmonary hypertension,
unaffected by any of the administered drugs or 100%
oxygen. Pulmonary capillary wedge pressure was normal,
as was arterial oxygen tension. Measurements at rest were
repeated after treatment for 1 week with nifedipine, 60
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mg·day-1, revealing no substantial effect of nifedipine.
After exercise, an increase in pulmonary arterial pres-
sure and a drop in mixed venous oxygen saturation were
found, indicating a severely disturbed pulmonary circu-
lation.
Phlebography of the TIPS shunt was repeated and
revealed no thrombosis or other abnormalities. At this
stage, liver transplantation was considered but rejected
because the patient continued to consume alcohol.  Grad-
ual right-sided heart failure developed, initially responding
to increasing doses of diuretics and angiotensin-conver-
ting enzyme (ACE) inhibitors. Eventually, the patient died
from severe right heart failure, with massive oedema, tense
ascites and sepsis.
At autopsy, micronodular cirrhosis of the liver (weight
2,300 g), splenomegaly (weight 1,000 g) and ascites were
found. The TIPS stent was in situ and patent despite a
small fresh thrombus lining the inner wall.  The lung tis-
sue was oedematous. Microscopically, the pulmonary
muscular arteries showed mild medial hypertrophy and
mild intimal fibrosis, mostly of the concentric-laminar
type (fig. 1a) but post-thrombotic lesions were rare.  Fib-
rinoid necrosis was observed in several arterial branches
and there were fairly numerous dilatation lesions and
plexiform lesions (fig. 1b). Recent thrombi were very
scarce.
Discussion
This patient developed severe, and ultimately fatal,
pulmonary hypertension 1.5 yrs following TIPS, a com-
plication which has not been described previously.  Clini-
cal evidence of pre-existing pulmonary hypertension or
other primary pulmonary or cardiac disease was absent.
Pulmonary wedge pressure was notably normal 1.5 yrs
after TIPS placement.  However, since pulmonary artery
pressures were not measured before TIPS, the possi-
bility that TIPS caused a worsening of pre-existing pul-
monary hypertension cannot be excluded.  If an increase
in venous return had caused pulmonary hypertension,
we would have expected symptoms to occur shortly after
TIPS placement, whereas our patient became sympto-
matic after 1.5 yrs. A rise in cardiac output, even with
a pre-existing slightly elevated mean pulmonary artery
pressure (Ppa), will not have led to such high values in
Ppa, as seen in our patient. Also, considering the charac-
teristic histological features of pulmonary hypertension,
we assume that an increased venous return was not of
major aetiological importance.
In patients with liver disease and portal hypertension, a
number of pulmonary complications have been described.
The most common pulmonary complication is the hepato-
pulmonary syndrome, caused by intrapulmonary vascular
Table 1.  –  Effects of vasodilator drugs on the circulation
Baseline  Prostacyclin  Nifedipine  After 1 week
8 ng·kg-1·min  0.2 mg·min-1 nifedipine
Ppa mmHg 38 39 45 50
Pcv mmHg 4 3 7 13
Pcwp mmHg 6 8 7 12
Q 'th L·min-1 8.2 10.6 9.3 9.8
Ppa: mean pulmonary artery pressure; Pcv: central venous pressure; Pcwp: pulmonary capi-
llary wedge pressure; Q 'th: cardiac output (thermodilution method).
Fig. 1.  –  a)  Muscular pulmonary artery with narrowing by concentric-laminar intimal fibrosis.  (Elastic van Gieson's stain; original magnifica-
tion ×180: scale bar = 50 µm).  b) Plexiform lesion in a branch immediately after its origin from a parent muscular pulmonary artery (Haematoxylin
and eosin stain; original magnification ×180: scale bar = 50 µm).
a) b)
dilatation with a resulting right-to-left intrapulmonary
shunt [4].  Pulmonary hypertension is much less frequent.
MCDONNELL et al. [5] found a prevalence of pulmonary
hypertension at autopsy of 0.73%. Another study report-
ed elevated pulmonary artery pressures in 2% of patients
with portal hypertension at the time of transvenous liver
biopsy [6].  Pulmonary hypertension has also been repor-
ted in patients with extrahepatic portal hypertension. In
patients with surgical portosystemic shunts, a relatively high
incidence has been suggested [6–9]. The most widely-
accepted hypothesis for pulmonary hypertension associa-
ted with portal hypertension is the shunting of vasoactive
substances, originating from the splanchnic vessels (and
usually inactivated in the liver) into the pulmonary vas-
culature, resulting in vasoconstriction and chronic arter-
ial changes. The same pathogenesis may have been present
in our patient.
Plexogenic pulmonary hypertension is initially charac-
terized by an increased arterial muscularity, followed by
cellular intimal proliferation and characteristic concentric-
laminar intimal fibrosis [10]. In the final stages of the
disease, fibrinoid necrosis and pathognomonic plexiform
lesions are found [10]. These abnormalities were all found
in our patient, with a marked abundancy of plexiform
lesions.
The therapeutic options in patients with pulmonary
hypertension are limited. In our patient, medical the-
rapy, including vasodilators and oxygen, failed to ame-
liorate haemodynamics. Although a beneficial effect of
liver transplantation has been reported [11], more data
are needed to define the place of this therapeutic option
in patients suffering from end-stage liver disease accom-
panied by pulmonary hypertension.
The morbidity and mortality associated with TIPS
has been reported to be relatively low, especially when
compared to surgical portosystemic shunts. Given the
previously reported higher incidence of pulmonary hyper-
tension after surgical shunting, and the increasing popu-
larity of TIPS, it can be expected that more cases will
be noted in the near future.  Unaltered pulmonary artery
pressures were found 1 months after TIPS [12], but stu-
dies with a more prolonged follow-up have not been
reported. Consideration should be given to measurement
of pulmonary artery pressures in each patient prior to
TIPS, and at each recatheterization performed either rou-
tinely after 3–6 months or when TIPS function seems
compromised, to establish pulmonary hypertension at an
early stage.  Undoubtedly, such measurements will leng-
then the procedure, albeit probably only to a minor degree.
Currently, it can be recommended that pulmonary embo-
lism is excluded, either by radiolabelled lung scanning
or angiography, and that pulmonary artery pressures are
measured in patients with otherwise not readily explained
dyspnoea following TIPS.
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